Therapeutic Response

ER negative, HER2-negative, and PR negative status confers therapeutic sensitivity to Sacituzumab govitecan in patients with Invasive Breast Carcinoma.

Statements

Source and description
Trodelvy (sacituzumab govitecan) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Trodelvy (sacituzumab govitecan) [product information]. EMA. The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
Sacituzumab Govitecan Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved sacituzumab govitecan for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
Trodelvy (sacituzumab govitecan) [product information]. EMA. The European Medicines Agency (EMA) has authorized sacituzumab govitecan as a monotherapy for the treatment of adult patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and who are not candidates for PD-1 or PD-L1 inhibitor therapy.